# Lars Hellerung Christiansen

> Lars Hellerung Christiansen is a Series A investor at Zealand Pharma backing Pharmaceutical. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Zealand Pharma](https://shizune.co/investors/profile/zealand-pharma)
- Total investments: 1
- Last investment: Jan 2025
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/lars-hellerung-christiansen-6a5b202/

Lars Hellerung Christiansen is a Series A investor at Zealand Pharma focused on Pharmaceutical. Lars Hellerung Christiansen

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Neumirna Therapeutics | Founded in 2020, NEUmiRNA focuses on achieving transformative disease modification for neurological conditions. | $20.6M | Series A | Jan 08, 2025 |  |

1 of 1 investments shown.

## Co-investors
- [Innovestor](https://shizune.co/investors/profile/innovestor) — VC Fund, 2 deals together
- [Angelini Ventures](https://shizune.co/investors/profile/angelini-ventures) — VC Fund, 1 deal together
- [Invivo Capital Partners](https://shizune.co/investors/profile/invivo-capital-partners) — VC Fund, 1 deal together

## About Zealand Pharma

VC Fund · Copenhagen, Denmark

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”) is a biotech company with leading-edge scientific expertise in turning peptides into medicines. Zealand has a growing proprietary pipeline of novel specialty drug candidates and a mature portfolio of products and projects under license collaborations with Sanofi, Helsinn Healthcare andBoehringer Ingelheim. Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of Type 2 diabetes, is marketed globally outside the US as Lyxumia:registered: by Sanofi and under regulatory review in the US. The license collaboration with Sanofi covers also a single-product combination of lixisenatide and insulin glargine (Lantus:registered:) which is on track for regulatory submission in the US in December 2015 and in the European Union in Q1 2016. The proprietary pipeline includes; danegaptide for ischemic reperfusion Injuries in Phase II development; ZP1848 for Short Bowel Syndrome in Phase II development; and the stable glucagon analogue, ZP4207, in Phase II preparation both as a single-dose rescue pen for severe hypoglycemia and for multiple-dose use to treat and control mild to moderate hypoglycemia; as well as several preclinical peptide therapeutics. The company is based in Copenhagen (Glostrup), Denmark. For further information about Zealand’s business and activities, please visit: www.zealandpharma.com or follow us on Twitter @ZealandPharma

5 contacts available at Zealand Pharma.

| Name | Title | Profile |
| --- | --- | --- |
| Adam Steensberg | Chief Executive Officer | https://shizune.co/investors/profile/adam-steensberg |
| Andrew Parker | Chief Scientific Officer, Executive Vice-President, Head of Research & External Innovation | https://shizune.co/investors/profile/andrew-parker-5 |
| Daan Ellens | Chairman of the Supervisory Board | https://shizune.co/investors/profile/daan-ellens |
| Lars Hellerung Christiansen | Co-Founder | https://shizune.co/investors/profile/lars-hellerung-christiansen |
| Marie Skovgaard | Director of Medicinal Chemistry | https://shizune.co/investors/profile/marie-skovgaard |

## Similar investors

### Similar industry
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Vaekstfonden](https://shizune.co/investors/profile/v%C3%A6kstfonden) — VC Fund
- [PSV](https://shizune.co/investors/profile/preseed-innovation) — VC Fund
- [Seed Capital](https://shizune.co/investors/profile/seed-capital) — VC Fund

## Featured in investor lists
- [Health Care Angel Investors in Denmark](https://shizune.co/investors/health-care-angel-investors-denmark)

## FAQ

### What does Lars Hellerung Christiansen invest in?

Lars Hellerung Christiansen invests primarily in Pharmaceutical startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Lars Hellerung Christiansen last invest?

The most recent investment recorded for Lars Hellerung Christiansen closed in Jan 2025. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co